Manila Times Business
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic condition, including asthma, concomitant food allergy, or atopic dermatitis.DBV will also present the clinical trial design of its recen
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Smart Powerr Corp. Announces Effective Date of Reverse Stock Split
2h ago
What caused the Sarangani offshore quake
2h ago
STAK Inc. to Launch AI-Ready Distributed Power Solutions Through Proposed U.S. Subsidiary
2h ago
Hulk Hogan died of natural causes Florida police report says in closing investigation
2h ago